Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Primary FIbrinolysis and Secondary STenting Versus immEdiate Stenting in ST-segment Elevation Myocardial Infarction (FISSTEMI)-- A Prospective Randomized Trial of Stent Implantation Strategy After Thrombolytic Therapy

NCT04663932 is registered in ClinicalTrials.gov with Harbin Medical University as lead sponsor.

NCT NCT04663932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04663932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Primary FIbrinolysis and Secondary STenting Versus immEdiate Stenting in ST-segment Elevation Myocardial Infarction (FISSTEMI)-- A Prospective Randomized Trial of Stent Implantation Strategy After Thrombolytic Therapy
Lead sponsor
Harbin Medical University
Phase
Not applicable
Overall status
Unknown status
Start date
December 22, 2020
Completion date
March 31, 2023
Enrollment
240 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome, arterial occlusive diseases, arteriosclerosis, cardiovascular diseases, coronary artery disease, coronary disease, heart diseases, myocardial ischemia, syndrome heart disease, vascular diseases